FI3215511T3 - Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa - Google Patents
Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa Download PDFInfo
- Publication number
- FI3215511T3 FI3215511T3 FIEP15857508.4T FI15857508T FI3215511T3 FI 3215511 T3 FI3215511 T3 FI 3215511T3 FI 15857508 T FI15857508 T FI 15857508T FI 3215511 T3 FI3215511 T3 FI 3215511T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- compound according
- pharmaceutical composition
- independently
- alkyl
- Prior art date
Links
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- -1 Cyan Chemical group 0.000 claims 3
- 208000015872 Gaucher disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076062P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/059541 WO2016073895A1 (en) | 2014-11-06 | 2015-11-06 | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3215511T3 true FI3215511T3 (fi) | 2024-05-16 |
Family
ID=55909884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15857508.4T FI3215511T3 (fi) | 2014-11-06 | 2015-11-06 | Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10570135B2 (enExample) |
| EP (2) | EP4406616A3 (enExample) |
| JP (2) | JP6734860B2 (enExample) |
| KR (1) | KR102662215B1 (enExample) |
| CN (2) | CN107001379B (enExample) |
| AU (1) | AU2015342887B2 (enExample) |
| DK (1) | DK3215511T3 (enExample) |
| EA (1) | EA201790995A1 (enExample) |
| ES (1) | ES2984482T3 (enExample) |
| FI (1) | FI3215511T3 (enExample) |
| HR (1) | HRP20240644T1 (enExample) |
| HU (1) | HUE066864T2 (enExample) |
| IL (1) | IL252053B2 (enExample) |
| LT (1) | LT3215511T (enExample) |
| MX (1) | MX394094B (enExample) |
| PL (1) | PL3215511T3 (enExample) |
| PT (1) | PT3215511T (enExample) |
| RS (1) | RS65642B1 (enExample) |
| SI (1) | SI3215511T1 (enExample) |
| SM (1) | SMT202400187T1 (enExample) |
| WO (1) | WO2016073895A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2681218T3 (es) * | 2010-12-08 | 2018-09-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| SMT202400187T1 (it) | 2014-11-06 | 2024-07-09 | Bial R&D Investments S A | Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici |
| JP6895439B2 (ja) | 2015-12-22 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体 |
| WO2017161137A1 (en) * | 2016-03-16 | 2017-09-21 | Lysosomal Therapeutics Inc. | Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| SG11201808830YA (en) | 2016-04-06 | 2018-11-29 | Lysosomal Therapeutics Inc | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP3440081A4 (en) * | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| JP7059268B2 (ja) | 2016-11-02 | 2022-04-25 | エフ．ホフマン－ラ ロシュ アーゲー | ＩＲＡＫ４モデュレーターとしてのピラゾロ［１，５ａ］ピリミジン誘導体 |
| US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
| CA3048357A1 (en) | 2016-12-29 | 2018-07-05 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
| EP3630766A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| US12064414B2 (en) * | 2017-12-20 | 2024-08-20 | Aizant Drug Research Solutions Private Limited. | Stable amorphous Eliglustat premix and process for the preparation thereof |
| JP2021506920A (ja) * | 2017-12-21 | 2021-02-22 | リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用 |
| EP3747885A4 (en) | 2018-01-31 | 2021-11-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| IT201800006067A1 (it) * | 2018-06-06 | 2019-12-06 | Nuovi inibitori della diidroortato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide. | |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| CN111217816B (zh) * | 2018-11-27 | 2022-08-16 | 中国科学院上海药物研究所 | 一类flt3激酶抑制剂及其制备和应用 |
| GB202211999D0 (en) * | 2022-08-17 | 2022-09-28 | Mironid Ltd | Compounds and their use as PDE4 activators |
| WO2025198486A1 (en) | 2024-03-22 | 2025-09-25 | BIAL – R&D Investments, S.A. | Process for preparing a pyrazolo[1,5-a]pyrimidinyl carboxamide compound |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| JP3763997B2 (ja) | 1999-05-13 | 2006-04-05 | 富士写真フイルム株式会社 | 感熱記録材料 |
| JP4331823B2 (ja) | 1999-05-21 | 2009-09-16 | 富士フイルム株式会社 | ピロロ［１，２−ａ］−１，３，５−トリアジン−４−オン系化合物 |
| BR0107456A (pt) | 2000-01-07 | 2002-10-08 | Transform Pharmaceuticals Inc | Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| JP4070966B2 (ja) | 2001-06-28 | 2008-04-02 | 株式会社カネボウ化粧品 | 新規ガラクトシルセラミド類縁体及び用途 |
| JP2005526003A (ja) | 2001-10-22 | 2005-09-02 | ファイザー株式会社 | ５−ｈｔ４受容体調節剤としてのイミダゾピリジン化合物 |
| EP1481977A4 (en) | 2002-03-01 | 2006-02-01 | Astellas Pharma Inc | NITROGENIC HETEROCYCLIC COMPOUND |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| BR0314584A (pt) | 2002-09-20 | 2005-08-09 | Pfizer | Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4 |
| AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| EP1620435A1 (en) | 2003-04-21 | 2006-02-01 | Pfizer Inc. | IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY |
| EP1682134A4 (en) | 2003-11-12 | 2008-10-15 | Amicus Therapeutics Inc | GLUCOIMIDAZOLE AND POLYHYDROXYCYCLOHEXENYL-AMINE DERIVATIVES FOR THE TREATMENT OF GAUCHER DISEASE |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| CN1922183B (zh) | 2004-02-18 | 2010-05-26 | 万有制药株式会社 | 含氮的稠合杂芳环衍生物 |
| WO2005113004A2 (en) | 2004-05-14 | 2005-12-01 | The Cleveland Clinic Founfation | Small molecule inhibitors for mrp1 and other multidrug transporters |
| AU2005254657B2 (en) | 2004-06-21 | 2011-03-17 | F. Hoffmann-La Roche Ag | Pyrrazolo-pyrimidine derivatives |
| MX2007001341A (es) | 2004-08-02 | 2007-04-23 | Sanol Arznei Schwarz Gmbh | Carboxamidas de indolizina y sus derivados aza y diaza. |
| DE102004049363A1 (de) | 2004-10-08 | 2006-04-13 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| WO2006078676A2 (en) | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| KR100968291B1 (ko) | 2005-02-11 | 2010-07-07 | 에프. 호프만-라 로슈 아게 | Ｍｇｌｕｒ２ 길항제로서의 피라졸로-피리미딘 유도체 |
| DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| KR20070122541A (ko) | 2005-04-21 | 2007-12-31 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Ｎ-치환 페닐아세트아미드 유도체 및 그것을 포함하는의약조성물 |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JP5102212B2 (ja) | 2005-10-06 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
| WO2007048066A2 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
| BRPI0619517A2 (pt) | 2005-12-08 | 2011-10-04 | Novartis Ag | ácidos pirazolo[1,5-a]piridina-3-carboxìlicos como inibidores de ephb e vegfr2 cinase |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| DK2040548T3 (da) | 2006-06-23 | 2012-08-13 | Amicus Therapeutics Inc | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| WO2008019363A2 (en) | 2006-08-07 | 2008-02-14 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5ht3 modulators |
| EP2094707A1 (en) | 2006-11-20 | 2009-09-02 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| US20080255153A1 (en) | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| BRPI0813216A2 (pt) | 2007-06-21 | 2014-12-23 | Irm Llc | Inibidores de proteínas cinases e métodos para usá-los. |
| JP5479105B2 (ja) | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| WO2009070567A1 (en) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| JP5394404B2 (ja) | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
| EP2269990A4 (en) | 2008-03-25 | 2012-04-18 | Takeda Pharmaceutical | Heterocyclic compound |
| CA2723135A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
| JP5749169B2 (ja) | 2008-10-14 | 2015-07-15 | アストラゼネカ アクチボラグ | 細菌感染の処置用の縮合スピロ環式ヘテロ芳香族化合物 |
| AU2009308675A1 (en) * | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ES2709108T3 (es) | 2009-08-17 | 2019-04-15 | Intellikine Llc | Compuestos heterocíclicos y usos de los mismos |
| BR112013000868A2 (pt) | 2010-07-13 | 2016-05-17 | Hoffmann La Roche | derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4 |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| ES2681218T3 (es) | 2010-12-08 | 2018-09-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pirazolopirimidinas sustituidas como activadoras de la glucocerebrosidasa |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| EP2688872A4 (en) * | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| HRP20160118T1 (hr) | 2011-08-18 | 2016-02-26 | Nippon Shinyaku Co., Ltd. | HETEROCIKLIÄŚKI DERIVAT KAO INHIBITOR MIKROSOMSKIH SINTAZA PROSTAGLANDINA E (mPGEs) |
| KR20140068112A (ko) | 2011-09-02 | 2014-06-05 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 치환된 융합 피리미딘 및 그의 용도 |
| US8961959B2 (en) | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CN104394869A (zh) | 2011-10-20 | 2015-03-04 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物 |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| EP2822944A1 (en) * | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| WO2013134336A2 (en) | 2012-03-09 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| AU2013240187A1 (en) | 2012-03-28 | 2014-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
| RU2014149684A (ru) | 2012-05-31 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Производные аминохиназолина и пиридопиримидина |
| BR112014030147B1 (pt) | 2012-06-22 | 2019-10-15 | Sumitomo Chemical Company, Limited | Compostos heterocíclicos fundidos, composição e método para controlar pestes |
| WO2014025651A1 (en) * | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
| AU2013311826A1 (en) | 2012-09-05 | 2015-03-26 | Bayer Cropscience Ag | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress |
| NZ707432A (en) | 2012-11-16 | 2020-01-31 | Univ Health Network | Pyrazolopyrimidine compounds |
| WO2014085607A1 (en) | 2012-11-29 | 2014-06-05 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| US9340546B2 (en) * | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| KR20140086002A (ko) | 2012-12-28 | 2014-07-08 | 한미약품 주식회사 | Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체 |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
| WO2015012328A1 (ja) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015026574A1 (en) | 2013-08-20 | 2015-02-26 | Bristol-Myers Squibb Company | Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| AR097543A1 (es) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| ES2687843T3 (es) | 2014-03-27 | 2018-10-29 | Academisch Medisch Centrum | Iminoazúcares N-(5-((aril o heteroril)metiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| SMT202400187T1 (it) | 2014-11-06 | 2024-07-09 | Bial R&D Investments S A | Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici |
| WO2017004408A1 (en) | 2015-07-01 | 2017-01-05 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| WO2017040877A1 (en) | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| LT3371190T (lt) | 2015-11-06 | 2022-08-10 | Incyte Corporation | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai |
| KR102782807B1 (ko) | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| CN108473501B (zh) | 2016-02-18 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 治疗化合物、其组合物及使用方法 |
| EP3440081A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| SG11201808830YA (en) | 2016-04-06 | 2018-11-29 | Lysosomal Therapeutics Inc | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017192841A1 (en) | 2016-05-04 | 2017-11-09 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192929A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| JP2021506920A (ja) | 2017-12-21 | 2021-02-22 | リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用 |
-
2015
- 2015-11-06 SM SM20240187T patent/SMT202400187T1/it unknown
- 2015-11-06 ES ES15857508T patent/ES2984482T3/es active Active
- 2015-11-06 PL PL15857508.4T patent/PL3215511T3/pl unknown
- 2015-11-06 MX MX2017005940A patent/MX394094B/es unknown
- 2015-11-06 JP JP2017544549A patent/JP6734860B2/ja active Active
- 2015-11-06 KR KR1020177015300A patent/KR102662215B1/ko active Active
- 2015-11-06 AU AU2015342887A patent/AU2015342887B2/en active Active
- 2015-11-06 LT LTEPPCT/US2015/059541T patent/LT3215511T/lt unknown
- 2015-11-06 PT PT158575084T patent/PT3215511T/pt unknown
- 2015-11-06 CN CN201580068129.9A patent/CN107001379B/zh active Active
- 2015-11-06 EP EP24166780.7A patent/EP4406616A3/en not_active Withdrawn
- 2015-11-06 WO PCT/US2015/059541 patent/WO2016073895A1/en not_active Ceased
- 2015-11-06 SI SI201532014T patent/SI3215511T1/sl unknown
- 2015-11-06 HU HUE15857508A patent/HUE066864T2/hu unknown
- 2015-11-06 HR HRP20240644TT patent/HRP20240644T1/hr unknown
- 2015-11-06 DK DK15857508.4T patent/DK3215511T3/da active
- 2015-11-06 IL IL252053A patent/IL252053B2/en unknown
- 2015-11-06 US US15/523,769 patent/US10570135B2/en active Active
- 2015-11-06 CN CN202211277924.7A patent/CN115925711A/zh active Pending
- 2015-11-06 EA EA201790995A patent/EA201790995A1/ru unknown
- 2015-11-06 FI FIEP15857508.4T patent/FI3215511T3/fi active
- 2015-11-06 RS RS20240536A patent/RS65642B1/sr unknown
- 2015-11-06 EP EP15857508.4A patent/EP3215511B1/en active Active
-
2017
- 2017-02-23 US US15/440,107 patent/US9732089B2/en active Active
-
2020
- 2020-01-03 US US16/733,598 patent/US11091492B2/en active Active
- 2020-07-10 JP JP2020119444A patent/JP7519221B2/ja active Active
-
2021
- 2021-07-07 US US17/369,507 patent/US11932645B2/en active Active
-
2024
- 2024-02-09 US US18/437,558 patent/US20250066364A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3215511T3 (fi) | Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa | |
| PH12017501061B1 (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| EP3699176A3 (en) | Antiviral compounds | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| MX337469B (es) | Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| WO2008107480A8 (en) | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators | |
| EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
| MX354134B (es) | Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias. | |
| PH12015502685A1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| MX2014006026A (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| AU2013261267A8 (en) | Carboxylic acid compounds | |
| MX2011011964A (es) | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. | |
| WO2009062676A3 (en) | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors | |
| MX2011011963A (es) | Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2). | |
| NZ596053A (en) | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| HRP20201379T1 (hr) | Antibakterijski spojevi koji imaju široki spektar djelovanja | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| NZ731897B2 (en) | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |